Stock A047920 HLB PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

HLB Pharmaceutical Co., Ltd Stock

Equities

A047920

KR7047920004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-14 pm EDT 		5-day change 1st Jan Change
32,550 KRW +3.01% Intraday chart for HLB Pharmaceutical Co., Ltd +2.68% +114.00%
2023 HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors CI
2023 HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors CI

Financials

Sales 2018 20.54B 14.71M Sales 2019 36.1B 25.85M Capitalization 75.19B 53.84M
Net income 2018 -7.06B -5.05M Net income 2019 473M 339K EV / Sales 2018 2.78 x
Net cash position 2018 1.41B 1.01M Net cash position 2019 1.96B 1.41M EV / Sales 2019 2.03 x
P/E ratio 2018
-8.1 x
P/E ratio 2019
159 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 82.36%
More Fundamentals * Assessed data

Chart HLB Pharmaceutical Co., Ltd

Dynamic Chart

Latest news about HLB Pharmaceutical Co., Ltd

HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors CI
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd. CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd. CI
Verismo Therapeutics, Inc. announced that it expects to receive KRW 12.138369345 billion in funding from HLB Pharmaceutical Co., Ltd CI
G-treeBNT Co., Ltd. announced that it has received KRW 95.000054256 billion in funding from a group of investors CI
HLB Pharmaceutical Co., Ltd(KOSDAQ:A047920) added to S&P Global BMI Index CI
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 95.000054256 billion in funding from a group of investors CI
Verismo Therapeutics, Inc. announced that it has received KRW 16.977 billion in funding from HLB Pharmaceutical Co., Ltd CI
Verismo Therapeutics, Inc. announced that it expects to receive KRW 16.977 billion in funding from HLB Pharmaceutical Co., Ltd CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 13.2 billion in funding CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 13.2 billion in funding CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from EBEST Investment & Securities Co., Ltd. CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from HLB Co., Ltd. and other investor. CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 48.632978215 billion in funding from EBEST Investment & Securities Co., Ltd., Medi Forum Co.,Ltd., HLB Co., Ltd. CI
More news

Quotes and Performance

1 day+3.01%
1 week+2.68%
Current month-11.55%
1 month+2.52%
3 months+148.47%
6 months+150.38%
Current year+114.00%
More quotes

Highs and lows

1 week
29 300.00
Extreme 29300
33 450.00
1 month
27 700.00
Extreme 27700
42 050.00
Current year
12 880.00
Extreme 12880
42 050.00
1 year
11 780.00
Extreme 11780
42 050.00
3 years
7 860.00
Extreme 7860
42 050.00
5 years
2 665.00
Extreme 2665
42 050.00
10 years
2 665.00
Extreme 2665
42 050.00
More quotes

Managers and Directors - HLB Pharmaceutical Co., Ltd

Managers TitleAgeSince
Jae-Hyeong Park CEO
 Chief Executive Officer 58 20-10-15
Bok-Hwan Jeon CEO
 Chief Executive Officer 60 20-10-15
Kang-Beom Kwon AUD
 Comptroller/Controller/Auditor 54 -
Members of the board TitleAgeSince
Tae-Hyeon Park BRD
 Director/Board Member 66 -
Jae-Hyeong Park CEO
 Chief Executive Officer 58 20-10-15
Bok-Hwan Jeon CEO
 Chief Executive Officer 60 20-10-15
More insiders

Quotes

Date Price Change Volume
24-04-15 32,550 +3.01% 831,554
24-04-12 31,600 +4.64% 685,893
24-04-11 30,200 -3.05% 850,830
24-04-09 31,150 -1.74% 2,115,515

End-of-day quote Korea S.E., April 14, 2024

More quotes

Company Profile

HLB Pharmaceutical Co Ltd, formerly Mediforum Pharmaceutical Inc, is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including cimetidine tablets, rozatin tablets, rabeprazole tablets, rozatinplus tablets, mosapia tablets and other ethical the counter (ETC) drugs; gynobetadine vaginal suppositories, and other over the counter (OTC) drugs; aceclofenac tablets, revotec tablets and other commissioned ETC drugs; L-carnitine tablets, elcatan tablets, hepatine liquids and other commissioned OTC drugs.
Sector
Pharmaceuticals
Calendar
2024-05-09 - Q1 2024 Earnings Release (Projected)
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
HLB PHARMACEUTICAL CO., LTD Stock HLB Pharmaceutical Co., Ltd
+114.00% 329M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+28.79% 676B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.94% 559B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.84% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.75% 320B
ABBVIE INC. Stock AbbVie Inc.
+4.32% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+4.00% 213B
NOVARTIS AG Stock Novartis AG
+1.92% 207B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 199B
PFIZER, INC. Stock Pfizer, Inc.
-10.00% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A047920 Stock